Trial Profile

A Multicenter, Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atacicept (Primary)
Indications IgA nephropathy
Focus Adverse reactions
Acronyms ORIGIN EXTEND
Sponsors Vera Therapeutics

Most Recent Events

17 Oct 2025 According to a Vera Therapeutics media release, data from this trial of atacicept will be delivered as a poster at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas, being held November 6 to 9.
19 Dec 2024 Status changed from not yet recruiting to recruiting.
11 Nov 2024 Planned initiation date changed from 1 Nov 2024 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com